Publications
View AllRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patien...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- KR
- Publications
- 4
- Citations
- 8,787
External Links
Identifiers
- ROR
- https://ror.org/005nteb15